Please login to the form below
Dragonfly Therapeutics
This page shows the latest Dragonfly Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Gilead signs $300m deal with Dragonfly to advance immunotherapies
The partnership will make use of Dragonfly’s oncology and inflammatory disease research capabilities. ... Gilead Sciences and Dragonfly Therapeutics have announced a new partnership focused on advancing Dragonfly’s novel natural killer (NK) cell
Latest news
-
BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme
Dragonfly will also receive up to 24% in royalties on worldwide net sales. ... In May, Dragonfly received investigational new drug approval for DF6002 from the US Food and Drug Administration.
-
Dragonfly signs Celgene as partner for NK cell platform
Extends presence in haemato-oncology and solid tumours. Immuno-oncology start-up Dragonfly Therapeutics has bagged a $24 million licensing deal from Celgene for two cancer therapeutics based on natural killer ... So far, the deals have meant Dragonfly
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
